Form 4: Amgen VP, Finance & CAO, Matthew C. Busch, Reports Changes in Beneficial Ownership
SEC Form 4
Matthew C. Busch, VP, Finance & CAO of Amgen Inc., reports changes in beneficial ownership of Amgen common stock due to the disposition of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On May 2, 2024, Matthew C. Busch, VP, Finance & CAO of Amgen Inc., reported changes in beneficial ownership of the company's common stock.
- The transaction involved the disposition of 27 shares of common stock at a price of $277.37 per share.
- These shares were disposed of to satisfy tax obligations related to the vesting of restricted stock units (RSUs).
- Following the transaction, Busch directly owns 4,626 shares of Amgen common stock.
- These shares include unvested Restricted Stock Units (RSUs) that will vest at various dates in the future.
- The shares also include Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing and has a neutral sentiment. It simply reports transactions related to executive stock ownership.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies like Amgen. It provides transparency regarding the financial interests of company insiders.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
- Companies like Johnson & Johnson, Pfizer, and Merck also have executives who regularly file Form 4s related to stock options and RSU vesting.
- The vesting schedules and equity incentive plans are generally comparable across large pharmaceutical companies.
Stakeholder Impact
- The transaction has a minimal direct impact on shareholders, employees, customers, suppliers, or creditors.
- It provides transparency regarding executive compensation and alignment with shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 05/02/2024 | Date of transaction (disposal of shares). |
| 05/05/2024 | 64 RSUs will vest. |
| 05/06/2024 | Date of report submission. |
| 04/30/2025 | 43 RSUs will vest. |
| 11/05/2024 | 494 RSUs will vest. |
| 11/05/2025 | 509 RSUs will vest. |
| 05/02/2025 | 71 RSUs will vest. |
| 05/02/2026 | 73 RSUs will vest. |
| 05/02/2025 | 97 RSUs will vest. |
| 05/02/2026 | 98 RSUs will vest. |
| 05/02/2027 | 101 RSUs will vest. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.